ARTA
RDHL

A.R.T. Advisors’s Redhill Biopharma RDHL Stock Holding History

A.R.T. Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13
Closed -$71K – 1553
2018
Q4 		$71K Buy
13
+1
+8% +$7.66K ﹤0.01% 1190
2018
Q3 		$101K Buy
+12
New +$97.8K ﹤0.01% 1276

Other funds holding RDHL

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

A.R.T. Advisors's RDHL Position: Q1 2019 in Review

A.R.T. Advisors sold out of Redhill Biopharma (RDHL) in Q1 2019, closing a stake of 13 shares — an estimated $71K sold.

A.R.T. Advisors first reported a position in RDHL in Q3 2018 and held it in 2 quarters. The position peaked at $101K in Q3 2018. 34 funds tracked by Wall St. Rank hold RDHL as of Q1 2019.

  • A.R.T. Advisors reported no remaining Redhill Biopharma position as of Q1 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 13 Redhill Biopharma shares in Q1 2019, an estimated $71K.
  • A.R.T. Advisors first reported a position in Redhill Biopharma in Q3 2018 and held it in 2 quarters.
  • A.R.T. Advisors's Redhill Biopharma position peaked at $101K in Q3 2018.
  • 34 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.